Drug intelligence / Profile preview

4HF-02

Development stage: Preclinical
Lead developer: 4HF Biotec
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

4HF-02 is an experimental small molecule drug conjugate (SMDC) currently in the discovery phase for the treatment of colon and pancreatic cancers. Developed by 4HF Biotec, the candidate is identified and optimized using an AI-driven platform that integrates data mining for cancer target identification. As an SMDC, 4HF-02 is designed to selectively deliver a therapeutic payload to tumor cells via a targeting ligand, aiming to enhance efficacy while minimizing systemic toxicity. The project is currently navigating in silico and medicinal chemistry stages.

Beyond the preview

Go deeper on 4HF-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4HF-02.

Explore the full profile